Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (42621)	1/13/1999 11:04:00 AM
From: ayahuasca	Read Replies (2) \| Respond to of 119973

I couldnt agree more. DCLK and NETG are the plays today.

To: QuietWon who wrote (42621)	1/13/1999 11:05:00 AM
From: Brukie	Respond to of 119973

From MM ASSASIN OF stock-dogs.com LIPO Im going to acumilate inher this is more than a day trade her potencial is stagering she is expecting the first profitable quoter in 17 years LIPO 13 11/16 right now mac divergence tuching and stochastics giving her a buy signal I want to see her try 16s atleast she is starting to move gona block play her 10:23 The Liposome Company Announces That it Expects to Report aProfitable Fourth Quarter SAN FRANCISCO, Jan. 13 /PRNewswire/ -- The Liposome Company, Inc. (Nasdaq-Amex: LIPO) announced today at the 17th Annual Hambrecht & Quist Healthcare Conference that it expects to report an operating profit for the fourth quarter of 1998. This is the Company's first quarterly operating profit in its 17-year history. The improved fourth quarter financial performance can be attributed to strong sales of ABELCET(R) and increased manufacturing efficiencies. For the nine months ended September 27, 1998, the Company previously reported a loss of $6.2 million or $0.16 per share compared to the 1997 nine-month loss of $19.2 million or $0.52 per share. The Company expects to issue 1998 fourth quarter and full year financial results during the week of February 8, 1999. The Liposome Company is a biopharmaceutical company developing, manufacturing and marketing therapeutic products to treat cancer and related diseases. ABELCET(R) (Amphotericin B Lipid Complex Injection), is marketed in the United States for the treatment of severe, systemic fungal infections in patients who are refractory to or intolerant of conventional therapy and is the leading lipid-based formulation of amphotericin B in this country. In December 1998, the Company filed a New Drug Application with the U.S. FDA for the Company's second drug, EVACET(TM) (formerly TLC D-99), liposomal doxorubicin, to treat metastatic breast cancer. The Company's product pipeline includes TLC ELL-12 and bromotaxol for the treatment of various cancers and programs focused on the development of new cancer therapies and vehicles for the delivery of gene therapy.